World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
86
Citations
43749
World Ranking
1228
National Ranking
79

Medicine

D-Index
87
Citations
43889
World Ranking
13406
National Ranking
715

Joachim R. Kalden publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Joachim R. Kalden sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 327 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Joachim R. Kalden D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Joachim R. Kalden sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 86 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Joachim R. Kalden was affiliated with the University of Erlangen-Nuremberg in Germany. The research primarily focused on the field of Medicine with a specialization in Rheumatology.

The scientist's work covered several subfields including:

  • Rheumatology
  • History
  • Dermatology
  • Clinical Psychology
  • Hematology

Key topics addressed in the research included:

  • Medical History and Research
  • Medicine and Dermatology Studies History
  • Historical Psychiatry and Medical Practices
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research

Joachim R. Kalden published papers in journals such as:

  • Aktuelle Rheumatologie
  • Zeitschrift für Rheumatologie

Notable publications include:

  • Zur Entwicklung der klinischen Rheumatologie in der Bundesrepublik Deutschland nach dem 2. Weltkrieg, 2021, Aktuelle Rheumatologie
  • 80 Meilensteine der Rheumatologie aus 80 Jahren - III: 1980-2000, 2021, Zeitschrift für Rheumatologie

Frequent co-authors associated with the scientist's work were:

  • Gerd-Rüdiger Burmester
  • Thomas Rose

Best Publications

  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

    R Maini;E W St Clair;F Breedveld;D Furst

  • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

    Lars Klareskog;Désirée van der Heijde;Julien P de Jager;Andrew Gough

  • Immunosuppressive effects of apoptotic cells

    Reinhard E. Voll;Martin Herrmann;Edith A. Roth;Christian Stach

  • Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

    M J Elliott;R N Maini;M Feldmann;J R Kalden

  • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

    Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen

  • Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

    Claudio Vitali;Stefano Bombardieri;Haralampos M. Moutsopoulos;Genesio Balestrieri

  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

    E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  • Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial

    Josef S Smolen;Joachim R Kalden;David L Scott;Blaz Rozman

  • Range of antinuclear antibodies in "healthy" individuals

    E. M. Tan;T. E. W. Feltkamp;J. S. Smolen;B. Butcher

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • IMPAIRED PHAGOCYTOSIS OF APOPTOTIC CELL MATERIAL BY MONOCYTE-DERIVED MACROPHAGES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

    Martin Herrmann;Reinhard E. Voll;Otmar M. Zoller;Manuela Hagenhofer

  • A rapid and simple method for the isolation of apoptotic DNA fragments

    M Herrmann;H M Lorenz;R Voll;M Grünke

  • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

    Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu

  • Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

    Peter Charles;Michael J. Elliott;Diana Davis;Alison Potter

  • The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

    Kirsten Neubert;Silke Meister;Katrin Moser;Florian Weisel

  • Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus.

    Irith Baumann;Wasilis Kolowos;Reinhard E. Voll;Bernhard Manger

  • Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE

    Vilma Urbonaviciute;Barbara G. Fürnrohr;Silke Meister;Luis Munoz

  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial

    Josef S. Smolen;Désirée M. F. M. Van Der Heijde;E. William St.Clair;Paul Emery

  • Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II.

    Martin A. Kriegel;Tobias Lohmann;Christoph Gabler;Norbert Blank

  • Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

    A Calin;B A C Dijkmans;P Emery;M Hakala

Frequent Co-Authors

Martin Herrmann
Martin Herrmann University of Erlangen-Nuremberg
Reinhard E. Voll
Reinhard E. Voll University of Freiburg
Udo S. Gaipl
Udo S. Gaipl University of Erlangen-Nuremberg
Bernhard Fleckenstein
Bernhard Fleckenstein University of Erlangen-Nuremberg
Paul Emery
Paul Emery University of Leeds
Thomas H. Winkler
Thomas H. Winkler University of Erlangen-Nuremberg
Gerd R. Burmester
Gerd R. Burmester Charité - University Medicine Berlin
Ferdinand C. Breedveld
Ferdinand C. Breedveld Leiden University Medical Center
Ravinder N. Maini
Ravinder N. Maini Imperial College London
Josef S. Smolen
Josef S. Smolen Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their career in immunology, pursuing related online degrees such as nursing practitioner programs can be a strategic move. Many students seek the cheapest psych np programs online to gain specialized skills without a heavy financial burden. These programs provide flexibility, allowing professionals to balance work and study effectively.

Once certified, salaries for advanced practice roles vary by location. Understanding how much do dnps make can help guide career decisions and negotiate fair compensation. This insight is particularly valuable for professionals seeking long-term stability in healthcare.

Transitioning between specialties is common in nursing careers. For example, nurses looking to focus on intensive care can explore pathways such as the acute care nurse practitioner certification, which enables them to handle more critical patient needs and broaden their expertise.

Additionally, accelerated options like the accelerated np program offer a faster route to certification, ideal for motivated individuals aiming to enter the workforce quickly. These programs are designed to meet the growing demand for qualified nurse practitioners in specialized fields related to immunology and healthcare.

Best Scientists Citing Joachim R. Kalden

Recently Published Articles